(Q38068116)

28 August 2017

1 reference

title

Adaptation or selection--mechanisms of castration-resistant prostate cancer (English)

1 reference

28 August 2017

1 reference

Andrew S Goldstein

2

0 references

author name string

Yang Zong

series ordinal

1

1 reference

28 August 2017

language of work or name

English

0 references

publication date

18 December 2012

1 reference

28 August 2017

published in

Nature Reviews Urology

1 reference

28 August 2017

volume

10

1 reference

28 August 2017

issue

2

1 reference

28 August 2017

page(s)

90-98

1 reference

https://scigraph.springernature.com/pub.10.1038/nrurol.2012.237

28 August 2017

exact match

0 references

cites work

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

STUDIES ON PROSTATIC CANCER

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

The current state of hormonal therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Converting cancer therapies into cures: lessons from infectious diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

The development of androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Molecular determinants of resistance to antiandrogen therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

In vivo knockdown of the androgen receptor results in growth inhibition and regression of well-established, castration-resistant prostate tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Abiraterone and increased survival in metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

The androgen axis in recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Androgen receptor (AR) aberrations in castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

In vivo amplification of the androgen receptor gene and progression of human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Integrative genomic profiling of human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

The mutational landscape of lethal castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Common structural and epigenetic changes in the genome of castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Advancing a clinically relevant perspective of the clonal nature of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Regulation of androgen receptor activity by tyrosine phosphorylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Molecular characterization of human prostate carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Prostatic cell lineage markers: emergence of BCL2+ cells of human prostate cancer xenograft LuCaP 23 following castration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Hormone refractory prostate cancer: Lessons learned from the PTEN prostate cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Role of autonomous androgen receptor signaling in prostate cancer initiation is dichotomous and depends on the oncogenic signal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

B-cell-derived lymphotoxin promotes castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Emergence of androgen independence at early stages of prostate cancer progression in Nkx3.1; Pten mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Stem-like cells with luminal progenitor phenotype survive castration in human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Androgen receptor mutations in high-grade prostate cancer before hormonal therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Primitive origins of prostate cancer: in vivo evidence for prostate-regenerating cells and prostate cancer-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Immunohistochemical Localization of the Androgen Receptor in Rat and Human Tissues*

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Widespread distribution of nuclear androgen receptors in the basal cell layer of the normal and hyperplastic human prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Basal epithelial stem cells are efficient targets for prostate cancer initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Immunohistochemical characterization of neuroendocrine cells in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Expression of basal cell keratins in human prostate cancer metastases and cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

A luminal epithelial stem cell that is a cell of origin for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Identification of a cell of origin for human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Pathogenesis of prostatic small cell carcinoma involves the inactivation of the P53 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Stem cells, cancer, and cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Cancer stem cells: impact, heterogeneity, and uncertainty

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

The cancer stem cell: premises, promises and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Tumour-initiating cells: challenges and opportunities for anticancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Cancer stem cells: an old idea--a paradigm shift

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Prospective identification of tumorigenic prostate cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Management of metastatic castration-resistant prostate cancer: recent advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: An early predictor of relapse or incomplete androgen suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Nuclear androgen receptor staining in bone metastases is related to a poor outcome in prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Endocrine Therapy for Prostate Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Insulin Increases De Novo Steroidogenesis in Prostate Cancer Cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Androgen receptors are differentially expressed in Gleason patterns of prostate cancer and down-regulated in matched lymph node metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Activation of programmed cell death in the rat ventral prostate after castration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRUROL.2012.237

Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor

31 March 2020

1 reference

12 December 2020

Collocation of androgen receptor gene mutations in prostate cancer

1 reference

12 December 2020

Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process

1 reference

12 December 2020

Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma

1 reference

12 December 2020

Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays.

1 reference

12 December 2020

Effective testosterone suppression for prostate cancer: is there a best castration therapy?

1 reference

12 December 2020

Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

1 reference

12 December 2020

Androgen receptor mutations in prostate cancer.

1 reference

12 December 2020

Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer

1 reference

12 December 2020

Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells.

1 reference

12 December 2020

Androgen-independent prostate cancer progression in the TRAMP model

1 reference

12 December 2020

Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status.

1 reference

12 December 2020

Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor

1 reference

12 December 2020

Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRUROL.2012.237

1 reference

Dimensions Publication ID

28 August 2017

1027918935

0 references

1 reference